Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2020 - 2026)

Monte Rosa Therapeutics' (GLUE) quarterly Total Non-Current Liabilities came in at $10.5 million in Q1 2026, down 13.22% quarter-over-quarter from $12.1 million in Q4 2025.

Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Monte Rosa Therapeutics' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $10.5 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $12.1 million, changed N/A from the prior year.
  • Total Non-Current Liabilities slipped to $10.5 million in Q1 2026 per GLUE's latest filing, from $12.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $101.2 million in Q3 2025 and bottomed at $10.5 million in Q1 2026.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Monte Rosa Therapeutics 2.30 Bn 1.62 Bn - 10.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 10.50 Mn
Dec 31, 2025 12.10 Mn
Sep 30, 2025 101.20 Mn
Dec 31, 2021 18.81 Mn
Sep 30, 2021 14.74 Mn
Jun 30, 2021 12.26 Mn
Dec 31, 2020 -37.42 Mn